As large-molecule drugs and weight-loss therapeutics dominate headlines, the pharmaceutical industry faces legislative pressures, funding cuts, and cascading supply chain disruptions.
Philip Morris International (PMI) is selling inhaled drug specialist Vectura to Molex Asia Holdings for a fraction of the £1.1 billion ($1.45 billion) it paid for the business three years a
Welcome back to Changing Faces for the month of July. Today we’re looking at CROs, CDMOs, suppliers, and tech vendors – the industry around pharma that keeps pharma ticking.
The pharmaceutical industry is undergoing a profound transformation, driven by the increasing complexity of drug development and the need for greater efficiency and cost-effectiveness.
Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and ac
Shares in WuXi Biologics and WuXi AppTec have tracked up after the BIOSECURE Act – which could have profound effects on their businesses in the US – was omitted from legislation due to be f
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year